Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 623-633

  Henderson, Gavin J ^a,b,d   Lee, Sook Kyung ^a   Irlbeck, David M ^a,b,e   Harris, Janera ^a   Kline, Melissa ^a   Pollom, Elizabeth ^a,b   Parkin, Neil ^c,f   Swanstrom, Ronald ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f DATA FIRST CONSULTING INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INDINAVIR; LOPINAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS ENVELOPE PROTEIN; ZIDOVUDINE;

AMINO ACID ANALYSIS; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; MURINE LEUKEMIA VIRUS; MUTANT; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; VIRION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; CELL LINE; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, ENV; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKEMIA VIRUS, MURINE; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; VIRION; VIRUS REPLICATION;

EID: 84862915396     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05549-11     Document Type: Article

References (62)

1. Ambrose Z, Julias JG, Boyer PL, Kewalramani VN, Hughes SH. 2006. The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J. Virol. 80:2578-2581. (Pubitemid 43271563)
2. Barbour JD, et al. 2002. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76:11104-11112. (Pubitemid 35176226)
3. Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A. 2001. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 75:3291-3300. (Pubitemid 32225892)
4. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. 2001. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75:4832- 4842.
5. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, Connick E. 2003. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J. Virol. 77:12105-12112. (Pubitemid 37339863)
6. Chen Z, et al. 1995. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270:21433-21436.
7. Colonno R, et al. 2004. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 189:1802-1810. (Pubitemid 38657216)
8. Condra JH, et al. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276. (Pubitemid 26378401)
9. Condra JH, et al. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
10. Croteau G, et al. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71:1089-1096. (Pubitemid 27030280)
11. Deeks SG, et al. 2002. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J. Infect. Dis. 185:315-323. (Pubitemid 34107244)
12. Deeks SG, et al. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480. (Pubitemid 32164898)
13. de la Carriere LC, Paulous S, Clavel F, Mammano F. 1999. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J. Virol. 73:3455-3459. (Pubitemid 29135741)
14. Derdeyn CA, et al. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367. (Pubitemid 30666686)
15. Detels R, et al. 1998. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280:1497-1503. (Pubitemid 28507402)
16. Douek DC, et al. 2002. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417:95-98. (Pubitemid 34498823)
17. Gotte M, Arion D, Parniak MA, Wainberg MA. 2000. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J. Virol. 74: 3579-3585. (Pubitemid 30180301)
18. Green N, et al. 1981. Sequence-specific antibodies show that maturation of Moloney leukemia virus envelope polyprotein involves removal of a COOH-terminal peptide. Proc. Natl. Acad. Sci. U. S. A. 78:6023-6027. (Pubitemid 12247457)
19. Gulnik SV, et al. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287.
20. Henderson LE, Sowder R, Copeland TD, Smythers G, Oroszlan S. 1984. Quantitative separation of murine leukemia virus proteins by reversed-phase high-pressure liquid chromatography reveals newly described gag and env cleavage products. J. Virol. 52:492-500. (Pubitemid 15202485)
21. Hinkley T, et al. 2011. A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase. Nat. Genet. 43:487-489.
22. Hirsch MS, et al. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA panel. JAMA 283:2417-2426. (Pubitemid 30257541)
23. Ho DD, et al. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020. (Pubitemid 24065777)
24. Hoffman NG, Schiffer CA, Swanstrom R. 2003. Covariation of amino acid positions in HIV-1 protease. Virology 314:536-548. (Pubitemid 37206360)
25. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM. 2003. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77:1512-1523. (Pubitemid 36055571)
26. Kaplan AH, et al. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. U. S. A. 91: 5597-5601. (Pubitemid 24174375)
27. Kempf DJ, et al. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469. (Pubitemid 32738004)
28. Kiernan RE, Freed EO. 1998. Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. J. Virol. 72:9621-9627. (Pubitemid 28520825)
29. Kimpton J, Emerman M. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
30. Ledergerber B, et al. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353:863-868. (Pubitemid 29126872)
31. Leigh Brown AJ, et al. 2004. Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J. Virol. 78:2242-2246. (Pubitemid 38228917)
32. Mammano F, Trouplin V, Zennou V, Clavel F. 2000. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 74:8524-8531. (Pubitemid 30666703)
33. Markowitz M, et al. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
34. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:3744-3752. (Pubitemid 29189817)
35. Maschera B, Furfine E, Blair ED. 1995. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:5431-5436.
36. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. 1999. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4:35-43. (Pubitemid 29386129)
37. Molla A, et al. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766. (Pubitemid 26225091)
38. Nijhuis M, et al. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
39. Palella FJ, Jr, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
40. Partaledis JA, et al. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
41. Patick AK, et al. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644. (Pubitemid 28462907)
42. Patick AK, et al. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297. (Pubitemid 26053135)
43. Pazhanisamy S, et al. 1996. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271:17979-17985. (Pubitemid 26250782)
44. Petropoulos CJ, et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928. (Pubitemid 30165271)
45. Rao JK, Erickson JW, Wlodawer A. 1991. Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry 30:4663-4671.
46. Rein A, Mirro J, Haynes JG, Ernst SM, Nagashima K. 1994. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J. Virol. 68:1773-1781. (Pubitemid 24065746)
47. Resch W, Parkin N, Stuelke EL, Watkins T, Swanstrom R. 2001. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc. Natl. Acad. Sci. U. S. A. 98:176-181. (Pubitemid 32095883)
48. Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. 2002. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76:8659-8666. (Pubitemid 34864060)
49. Rhee SY, et al. 2010. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 54:4253-4261.
50. Sampah ME, Shen L, Jilek BL, Siliciano RF. 2011. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 108:7613-7618.
51. Sarafianos SG, et al. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. U. S. A. 96:10027-10032. (Pubitemid 29422506)
52. Schagger H, von Jagow G. 1987. Tricine-sodium dodecyl sulfatepolyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal. Biochem. 166:368-379. (Pubitemid 18004907)
53. Schock HB, Garsky VM, Kuo LC. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. 271:31957-31963. (Pubitemid 26422220)
54. Shen L, et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766. (Pubitemid 351951518)
55. Shen L, et al. 2011. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci. Transl. Med. 3:91ra63.
56. Tong W, et al. 1997. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 36:5749-5757. (Pubitemid 27214926)
57. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905. (Pubitemid 34535213)
58. Whitehurst N, Chappey C, Petropoulos C, Parkin N, Gamarnik A. 2003. Polymorphisms in p1-p6/p6*of HIV type 1 can delay protease autoprocessing and increase drug susceptibility. AIDS Res. Hum. Retroviruses 19:779-784. (Pubitemid 37215133)
59. Wu TD, et al. 2003. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77:4836-4847. (Pubitemid 36402833)
60. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306. (Pubitemid 28175575)
61. Zhang YM, et al. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.
62. Ziermann R, et al. 2000. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. 74:4414-4419. (Pubitemid 30214449)